X4 Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon, everybody. My name is Gil Blum, and I am a senior analyst at Needham and Company covering companies particularly in oncology space. It is my pleasure to have Paula Ragan here from X4 with me, and she will discuss X4's recent progress and clinical programs. Paula?
Thanks so much, Gil. We appreciate the chance to present at the Needham conference. Just as a reminder, I'll be making forward-looking statements. We encourage everybody to review our most recent 10-K filing for specifics around our risks and forward-looking statements.
So I'm very pleased to share the X4 story with you where we're focused on developing innovative treatments for rare diseases that are caused by a dysregulated immune system. The immune system is so critical in health and well-being. And there's several areas that we believe our once-daily oral can address and create dramatic impact favorably for patients in the US and worldwide, potentially treating over
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |